Christine Labeur

USPTO Granted Patents = 8 (Patent Applications = 5)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 45(Granted Patents)

Location History:

Brugge, BE (1998)
Bruges, BE (2013 - 2021)

Company Filing History:

N.v. Innogenetics S.a.

Years Active: 1998-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12116607 - Method for the production of domain antibodies (2024-10-15),

2. 10919954 - Antigen binding dimer-complexes, methods of making/avoiding and uses thereof (2021-02-16),

3. 10005830 - Antigen binding dimer-complexes, methods of making/avoiding and uses thereof (2018-06-26),

4. 9884117 - Stable formulations of polypeptides and uses thereof (2018-02-06),

5. 9464138 - Method for the production of domain antibodies (2016-10-11),

6. 9265834 - Stable formulations of polypeptides and uses thereof (2016-02-23),

7. 8343932 - Protease-sensitive site in apolipoprotein A1, therapeutic and diagnostic implications (2013-01-01),

8. 5733879 - Peptides and proteins, process for their preparation and their use as (1998-03-31),

Title: Discovering the Innovations of Christine Labeur

Introduction

Christine Labeur is an accomplished inventor based in Bruges, Belgium. With a remarkable portfolio, she holds seven patents that reflect her expertise and dedication to the field of biochemistry and biotechnology. Her contributions have potential applications in medicine and biochemical research, making her a significant figure in her area of innovation.

Latest Patents

Among her latest inventions is a method for the production of domain antibodies. This innovative method involves promoting the formation of disulfide bridges in domain antibodies through the addition of oxidizing agents, particularly oxidizing metal ions such as Cu2+, Fe2+, Fe3+, and Zn2+.

Another notable patent concerns antigen binding dimer-complexes, which comprises single variable domains. The invention describes novel dimer-complexes, referred to as non-fused dimers (NFDs), which consist of either identical monomers (homodimers) or different monomers (heterodimers). These complexes exhibit improved binding characteristics compared to their monomeric counterparts. The invention also outlines methods to engineer the stability of these NFDs and the conditions necessary for their formation or avoidance.

Career Highlights

Throughout her career, Christine has worked with leading biotechnology firms such as Ablynx and Pronota. Her work has spanned various innovative projects, particularly those focused on developing next-generation therapeutic agents that leverage her expertise in antibody technology.

Collaborations

Christine has collaborated with notable professionals in her field, including Marc Jozef Lauwereys and Ann Brige. These collaborations have facilitated shared knowledge and advancement in their respective projects, enhancing the impact of their innovations in the industry.

Conclusion

Christine Labeur’s contributions to the field of biotechnology through her patents and collaborations exemplify the power of innovation in enhancing medical science. Her groundbreaking work not only advances our understanding of antibody production but also opens new avenues for therapeutic applications. With seven patents to her name, Christine continues to inspire fellow inventors and researchers in the pursuit of innovative solutions.

This text is generated by artificial intelligence and may not be accurate.